title: Glucose transporter-1 as a new therapeutic target in laryngeal carcinoma.
abstract: Treatment options for laryngeal carcinoma, one of the most common head and neck malignancies, consist of radiotherapy, surgery, chemotherapy or a combination thereof. The functional treatment of laryngeal carcinoma poses a considerable challenge because of its resistance to chemotherapy and radiotherapy, and its tendency for local recurrence. Finding ways to inhibit the energy supply of malignant tumours is becoming an increasingly attractive proposition. Glucose transporter-1 (Glut-1; encoded by the SLC2A1 gene in humans) is the main transporter of glucose in solid carcinomas and has become a focus of cancer research. Recently, it was shown that the increased expression of SLC2A1 in head and neck carcinomas is correlated with lymph node metastasis, poor survival and clinical stage, and revealed that the suppression of SLC2A1 expression by antisense oligodeoxynucleotides decreased glucose uptake and inhibited the proliferation of Hep-2 cells. Thus, the authors propose the suppression of SLC2A1 expression as a new therapeutic target for laryngeal carcinoma.
authors.affiliation: Department of Otolaryngology, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
authors.forename: X-M
authors.initials: XM
authors.lastname: Luo
authors.forename: S-H
authors.initials: SH
authors.lastname: Zhou
authors.forename: J
authors.initials: J
authors.lastname: Fan
mesh_terms: D005947:Glucose / Q000031:analogs & derivatives; D051272:Glucose Transporter Type 1 / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D007822:Laryngeal Neoplasms / Q000628:therapy*; D058990:Molecular Targeted Therapy; D034622:RNA Interference; D015398:Signal Transduction
chemical_list: D051272:Glucose Transporter Type 1; D005947:Glucose